Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85

Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85

Sponsors

Lead Sponsor: The University of Queensland

Collaborator: Griffith University
The Prince Charles Hospital
Princess Alexandra Hospital, Brisbane, Australia
Telethon Kids Institute
Queensland Children's Hospital, South Brisbane, Queensland, Australia

Source The University of Queensland
Brief Summary

Parallel group, Wait-list design, with treatment delayed for 3 months. Participants will be randomized on a 1:1 ratio with 500 participants per group in Australia. Group 1: Wait-list control. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment. Group 2: Initial treatment. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.

Detailed Description

The Covid-19 pandemic has been characterised by acute respiratory distress syndrome (ARDS) accompanied by a systemic cytokine-storm resulting in severe illness, respiratory failure and death in some. Severe Acute Respiratory Syndrome (SARS)- Coronavirus (Cov-2) (COV) infection per se is not the only underlying issue here, as it is becoming evident that ARDS is relatively rare amongst infected subjects, and appears to be associated with gross dysregulation of ensuing host-anti-viral responses resulting in collateral immune-inflammatory-mediated damage to host tissues. Rather than waiting for susceptible subjects to present with COV-associated ARDS, the investigators propose treatment of healthy health care workers (HCW) with a therapeutic agent which simultaneously targets front-line innate anti-viral immune defences, together with the core mechanism that controls immune response intensity in the airways. This research addresses the hypothesis that resistance to development of severe COV-associated respiratory disease in front-line HCW, even in those who develop a primary infection, can be boosted via a regimen of daily dosing with the bacterial-derived immunomodulatory agent OM85. Aims 1. To demonstrate that daily treatment with OM85 will prevent HCW developing acute respiratory infections (ARI) necessitating removal from the workforce. 2. To elucidate the mechanism of action by which OM85 regulates host immune responses against COV. Mechanistic studies will primarily test the hypothesis that OM85 pre-treatment modulates the systemic immunoinflammatory response to COV, selectively attenuating potentially pathogenic pro-inflammatory pathways without compromising activation of innate immune pathways central to pathogen clearance. The investigators will additionally collect samples to test the secondary hypothesis that the host response to COV displays uniquely aggressive pro-inflammatory features that differ from those observed with non-COV respiratory infections. Experimental design: participants will be randomised into two groups; Immediate treatment with OM85 (n=500) or wait-list control with OM85 commencing three months later (n=500). Venous blood samples will be collected from each subject at four time points. Sera will be stored from each time point for assay of COV-specific antibody. For the mechanistic studies the investigators will focus on two groups of subjects who test respectively positive or negative to COV during a defined respiratory illness. These will be further stratified by treatment (OM85 treated (OM+) versus non-treated (OM-) prior to ARI, yielding 4 sets (each n=50) of test samples collected at acute infection which will be utilized for two discrete cross-comparisons: (i) COV+/OM+ versus COV+/OM-, and (ii) COV-/OM+ versus COV-/OM-. Analyses in (i) will be prioritised as they relate exclusively to host-responses to COV and effects of treatment thereon; those in (ii) which will contrast COV-associated response with those elicited by conventional respiratory pathogens and compare respective susceptibility to OM85.

Overall Status Completed
Start Date 2020-08-24
Completion Date 2021-09-30
Primary Completion Date 2021-06-30
Phase Phase 3
Study Type Interventional
Primary Outcome
Measure Time Frame
Acute Respiratory Infection necessitating workforce removal 3 months
Secondary Outcome
Measure Time Frame
Time to ARI necessitating workforce removal. 12 months
The proportion of Health Care Workers contracting an Acute Respiratory Infection necessitating workforce removal 12 months
The proportion of HCW with documented Cov infection. 12 months
Time to Lower respiratory infection (LRI) necessitating workforce removal. 12 months
The proportion of Health Care Workers contracting a LRI necessitating workforce removal 12 months
The proportion of HCW with documented Cov LRI. 12 months
Enrollment 59
Condition
Intervention

Intervention Type: Drug

Intervention Name: Broncho-Vaxom®

Description: Broncho-Vaxom adult capsules® (OM85)

Other Name: OM85

Eligibility

Criteria:

Inclusion Criteria: Participants who meet all of the following criteria are eligible for enrolment: 1. HCW in front line clinical departments assessing or caring for patients with suspected or verified COV infection in one of the recruiting hospitals in Brisbane 2. Participants who, in the opinion of the investigator, are able to comply with the protocol for its duration, 3. Written informed consent signed and dated according to local regulations. Exclusion Criteria: Participants who meet any of these criteria are not eligible for enrolment: - Staff with prior COV infection necessitating workforce removal

Gender:

All

Minimum Age:

18 Years

Maximum Age:

100 Years

Healthy Volunteers:

Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
PETER D SLY, DSc Principal Investigator The University of Queensland
Overall Contact Contact information is only displayed when the study is recruiting subjects.
Location
Facility:
The Prince Charles Hospital | Brisbane, Queensland, 4032, Australia
The Princess Alexandra Hospital | Brisbane, Queensland, 4102, Australia
Queensland Children's Hospital | South Brisbane, Queensland, 4101, Australia
Location Countries

Australia

Verification Date

2021-09-01

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: Wait-list control

Type: Active Comparator

Description: One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment.

Label: Initial treatment wtih OM85

Type: Experimental

Description: One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.

Acronym COVIDRASP
Patient Data No
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Intervention Model Description: Participants will be randomized to either Group 1 (waitlist control, delayed treatment group) or Group 2 (initial treatment) for treatment for a period of 3 months with 3 months follow-up off treatment

Primary Purpose: Prevention

Masking: None (Open Label)

Masking Description: Participants will be randomised to the wait list group (Group 1) or the initial intervention group (Group 2) using a one-to-one ratio, stratified by hospital and department [High risk, lower risk].

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Respiratory Viral Infection

Clinical Trials on Broncho-Vaxom®